ABSTRACT
The recent reports on developments in pharmaceutical research shows a decline in success of new pharmaceutical compounds in market last ten years due to which the time of new drug development also increased from 9 to 14 years. Drug repurposing is a method to use old drugs by repositioning them, which can reduce the new drug development time and cost. Drug repurposing also helps in predicting new therapeutic potentials of old drugs approved by FDA. Some of the commonly repurposed drugs are: metformin designed for diabetes type 2, now repurposed for cancer therapeutic and under clinical trial phase III, sildenafil and thalidomide designed for sickness and angina now repurposed for leprosy and erectile dysfunction. Due to limited data availability on cardiovascular profile of anti-inflammatory drugs the use of 148these drugs are limited. Drug repurposing is a great tool to identify safety of different drugs in CVD condition. The data of different studies available till now shows possibility of monoclonal antibodies as target therapy for CVDs in coming years. Data of anti-inflammatory drugs like colchicine that have been repurposed for CVDs shows promising results in patients of STEMI. Similarly Metformin, an anti-diabetic drug also shows effective inflammatory process control and cardioprotective properties. The future studies need more evidences from clinical trials to better repurpose these drugs and their approval to be used in CVDs.
